HR Chest CT Visual Scoring, Spirometry and Health Related Quality of Life in Evaluating Severity of ILD Patients

Interstitial Lung Disease Clinical Trial

Official title:

High-resolution Chest CT Visual Scoring, Spirometry and Health Related Quality of Life in Evaluating Severity of Interstitial Lung Disease Patients

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05999838
• Other study ID #: HR chest CT spirometry ILD
• Status: Not yet recruiting
• Start date: October 2023
• Est. completion date: February 2025

Study information

• Verified date: August 2023
• Source: Assiut University
• Contact: Dina W. Fahim, resident doctor
• Phone: 01287799134
• Email: tinawageh0[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To establish a simplified approach for assessment of severity of interstitial lung disease by evaluating the relationship between HRCT findings, the clinical severity score,spirometry and quality of life.

Description:

The interstitial lung diseases are a group of parenchymal pulmonary disorders that affect the interstitium causing progressive fibrosis of lung tissue. These disorders characterized by dyspnea aggravated by exertion . This group of diseases is associated with substantial morbidity and mortality. Thus, a multi-disciplinary approach including clinical, pathological, and radiological correlation is required to reach accurate assessment. The high-resolution computed tomography [HRCT] images of the chest are considered the main platform for the diagnostic approach .High-resolution CT (HRCT) scans offer the possibility of measuring disease severity more accurately and sensitively by focusing on fibrotic changes. HRCT images illustrate the presence and extent of parenchymal abnormalities including: reticular opacities, ground-glass opacities, traction bronchiectasis and honeycombing. Most patients with suspected ILDs are likely to undergo complete Pulmonary Function Testing. Usually there is restrictive pulmonary function with decreased TLC (Total Lung Capacity) , FVC (Forced Vital Capacity), FEV1 (Forced Expiratory Volume in One Second) and a normal or increased FEV1/FVC ratio.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: February 2025
• Est. primary completion date: October 2024
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• All patients admitted at Chest Department or presented to our out patient clinic with clinical diagnosis of Interstitial Lung Diseases among both sexes

Exclusion Criteria:

• patients under 18 years old.

• pregnant patients.

• patients with a history of previous lung resections.

• presence of bronchial carcinoma or lobar consolidation.

• patients contraindicated to perform pulmonary function will be excluded.

Related Conditions & MeSH terms

• Interstitial Lung Disease
• Lung Diseases
• Lung Diseases, Interstitial

Intervention

Diagnostic Test:
• HRCT chest visual scoring
CT-based semi-quantitative scoring will be calculated according to number of lung segments affected on both sides. The finding on each segment will be given a score from 1 to 4 as follows: for ground glass opacities. for reticulations and fibrotic changes. for bronchiectatic changes. for honeycombing and sub-pleural cysts.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation of visual based scoring system of HRCT and pulmonary function test.		1 year
Secondary	assessment of ILDs patients quality of life and correlation with HRCT finding and PFTs.		1 year